Generally speaking, bilastine should be discontinued once symptoms have resolved, and it should be recommenced if symptoms reappear. However, in perennial allergic rhinitis, continued treatment is advisable during the period of allergen exposure. In clinical studies to date, the longest period of treatment has been 12 months in patients with perennial allergic rhinitis. In this open-phase study, following a controlled comparison of bilastine with cetirizine 10 mg and placebo, bilastine was well tolerated. On the basis of these findings, it seems reasonable to think that bilastine should be administered for as long as symptoms persist.
